American Thoracic Society (ATS)

Congress registration Link

Design of a Phase 1 Virtual Hybrid Study of AZD7594, an Inhaled Non-steroidal, Selective Glucocorticoid Receptor Modulator, in Adolescents with Asthma  

Safety, Tolerability and Pharmacokinetics (PK) of AZD8154, a Selective PI3Kγδ Inhibitor, After Single and Multiple Ascending Inhaled Doses in Healthy Volunteers

Exacerbation Reduction and Early Improvements in SGRQ, Lung Function, and Symptoms of Nasal Polyposis with Benralizumab for Severe, Eosinophilic Asthma: Phase IIIb ANDHI Trial

Enabling Reductions in Maintenance ICS/LABA Therapy Using As Needed Anti-Inflammatory Reliever for Patients with Severe Eosinophilic Asthma Controlled with Benralizumab: SHAMAL Phase IV Clinical Study

Distinct Sputum Microbiome Profiles Before and After Benralizumab Therapy in Eosinophilic Chronic Obstructive Pulmonary Disease

Improvement of Clinical Outcomes in Severe, Eosinophilic Asthma Patients Treated with Benralizumab in Real-World Clinical Practice in England: XALOC Study Programme

Evaluation of the Efficacy and Safety of As-needed PT027 (budesonide/albuterol MDI) Compared to As-needed Albuterol MDI in Adults and Children 4 Years of Age or Older with Uncontrolled Moderate to Severe Asthma: Design of the MANDALA Study

Single-Inhaler Triple Combination Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) at Two Corticosteroid Dose Levels in COPD: ETHOS trial

Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) and All-Cause Mortality versus LAMA/LABA in COPD: Sensitivity Analysis of All-cause Mortality (Secondary Endpoint) in the ETHOS Trial with Final Retrieved Vital Status Data

Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) on Symptoms and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the ETHOS Trial

Improvements in Lung Function with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies in Patients with COPD: A Sub-study of the ETHOS Trial

Cardiovascular Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-suspension Delivery Technology in Chronic Obstructive Pulmonary Disease (COPD): A 24-hour Holter Monitoring Sub-study of the ETHOS Trial

The Cost of a Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation, Estimated from Recent Triple Therapy Studies in Patients with COPD: KRONOS and ETHOS

Factors Associated with Asthma Hospitalization Among US Adults with Severe Asthma Enrolled in the CHRONICLE Study

Maintenance Systemic Corticosteroid Use is Associated with Multiple Adverse Conditions in U.S. Adults with Severe Asthma: Results from the CHRONICLE Study

Evaluation of the Role of Hedgehog Interacting Protein (HHIP) and the Sonic Hedgehog Pathway to Enhance Respiratory Repair and Function in Chronic Obstructive Pulmonary Disease (COPD)

Toxin Neutralization Therapy Protected Against Staphylococcal Septic Shock – Results from an Experimental Intensive Care Unit Using Outbred Rabbits 

Proteomic Profiling Reveals Heterogeneity of Chronic Obstructive Pulmonary Disease  with Differential Anti-microbial, Pro-survival and Lung Regeneration Activities 

Elucidation of the Role of the C-C Chemokine Receptor (CCR10) in Mesenchymal Progenitor Cells in IPF

Filaggrin Truncating Variants Identify a New Subgroup of Children at Risk of Developing Asthma, Irrespective of Allergy Status

A Rare IL-33 Loss-of-Function Splice Variant Protects Against Early Onset Asthma

Genetic Analysis Identifies a Novel Missense Variant in SPDL1 Associated with Idiopathic Pulmonary Fibrosis

Whole Exome Analysis Associates Hemicentin1 with Lung Function, Pointing Towards a Potential Role in IPF

Type 2 Inflammation in Eosinophilic Chronic Obstructive Pulmonary Disease

Systemic Biomarkers of Lung Function and FEV1 Decline across Multiple Cohorts

Asthma Education Survey in Argentina: Current Situation and Development of Training Material

A Global Survey of Blood Eosinophil Distribution in Severe Asthma Patients: Data from the International Severe Asthma registry (ISAR)

Characterization of Eosinophilic and Non-eosinophilic Severe Asthma Phenotypes and Proportion of Patients with These Phenotypes in the International Severe Asthma registry (ISAR)

Biomarker Relatability in the International Severe Asthma Registry

Biologic Utilization Patterns: Data from the International Severe Asthma Registry (ISAR)

Global Access for Biologics in the Treatment of Severe Asthma: A Challenge to Personalized Medicine

The Impact of Exacerbation Burden on Lung Function Trajectory in a Broad UK Asthma Population: A Large Longitudinal Cohort Study

Validation of the Respiratory Symptoms Questionnaire in the NOVELTY Study

Genetic Analysis of 1,977 Patients with Obstructive Respiratory Disease in the NOVEL observational longiTudinal studY (NOVELTY)

Frequent Cough and/or Mucus Production Across Physician-assigned Severity Groups in Patients with Obstructive Lung Disease in the NOVELTY Study

Regional Variation in Asthma Prevalence and Oral Corticosteroid Use for Canadian Patients: Heat Map Analysis

The Relationship Between Asthma Control as Measured by the Asthma Impairment and Risk Questionnaire (AIRQ™) and Health-related Quality of Life (HRQoL)

Assessing Asthma Control in the United States by Examining the Relationships Between Short-acting Beta2-agonist and Systemic Corticosteroid Use

Patient Clinical Characteristics and Biomarkers Associated with Underlying Exacerbation Risk in Asthma

Frequency and Characteristics of U.S. Patients with Severe Asthma Receiving Specialty Care

Asthma Disease Burden in US Children Aged 4-11 Years as Revealed by Real-world Patterns of Short-acting Beta-agonist and Systemic Corticosteroid Use

Disease Burden Associated with Real-world Patterns of Short-acting Beta2-Agonist and Systemic Corticosteroid Use Among Patients with Mild Asthma

Disease Burden for Patients with Chronic Obstructive Pulmonary Disease Receiving Maintenance Therapy

Economic Burden of Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review

Real-life Treatment Patterns and Burden of Disease Among Patients with COPD – A Large Observational Study

Saracatinib, a Novel Therapeutic Approach for Pulmonary Fibrosis 

The Effect of Tezepelumab on Exacerbations in Patients with Severe Uncontrolled Asthma According to Baseline Serum IL-5 and IL-13 levels: Results from the Phase 2b PATHWAY Study

Seasonal Variability of Exacerbations in Patients with Severe, Uncontrolled Asthma and Clinical Benefits of Tezepelumab: Results from the PATHWAY Phase 2b Study

Effects of Tezepelumab on Asthma Exacerbations and Type 2 Biomakrers in Patients with Severe, Uncontrolled Asthma With and Without Nasal Polyps: Results from a Post-hoc Analysis of the Phase 2b PATHWAY Study

Eosinophil Counts and Fractional Exhaled Nitric Oxide Levels After Cessation of Tezepelumab: Results from the PATHWAY Phase 2b Study

Inhaled Triple Therapy at Two Glucocorticoid Doses in Moderate-to-Very Severe COPD: The ETHOS Study